TD Cowen on Amylyx Pharmaceuticals inc. (AMLX): 'continue to see AMLX as undervalued for the potential of avexitide alone'

Go back to TD Cowen on Amylyx Pharmaceuticals inc. (AMLX): 'continue to see AMLX as undervalued for the potential of avexitide alone'
(NASDAQ: AMLX) Delayed: 21.63 -0.85 (3.78%)
Previous Close $22.48    52 Week High
Open $22.35    52 Week Low
Day High $22.39    P/E N/A 
Day Low $21.29    EPS
Volume 1,588,782